Odstock Medical Limited Sustainability Profile
Odstock Medical Limited, headquartered in Great Britain, is a pioneering company in the medical technology industry, specialising in innovative solutions for neuromuscular stimulation. Founded in 1993, Odstock Medical has established itself as a leader in the development of advanced therapeutic devices, particularly in the field of rehabilitation and pain management. The company is renowned for its unique products, including the Odstock Dropped Foot Stimulator (ODFS), which enhances mobility for individuals with foot drop due to neurological conditions. With a commitment to quality and innovation, Odstock Medical has achieved significant milestones, including expanding its operational reach across Europe and beyond. Their dedication to improving patient outcomes has solidified their position as a trusted name in medical technology, making a meaningful impact in the lives of many.
DitchCarbon Score
How does Odstock Medical Limited's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Odstock Medical Limited's score of 24 is higher than 52% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Odstock Medical Limited's reported carbon emissions
In 2023, Odstock Medical Limited reported total carbon emissions of approximately 73,670 kg CO2e. This figure includes 1 kg CO2e from Scope 1 emissions, which are direct emissions from owned or controlled sources. Scope 2 emissions, related to the generation of purchased electricity, steam, heating, and cooling, accounted for about 32,130 kg CO2e. The majority of their emissions, approximately 41,540 kg CO2e, fall under Scope 3, which includes indirect emissions from the value chain. Notably, business travel contributed about 4,550 kg CO2e, while employee commuting accounted for approximately 14,634 kg CO2e. Currently, Odstock Medical Limited has not set specific reduction targets or initiatives, nor do they participate in any recognised climate pledges such as the Science Based Targets initiative (SBTi). The absence of formal commitments suggests a need for further development in their climate strategy. As of now, their emissions data is not cascaded from any parent or related organization, indicating that these figures are solely representative of their own operations.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2023 | |
|---|---|
| Scope 1 | 1 |
| Scope 2 | 32,130 |
| Scope 3 | 41,540 |
How Carbon Intensive is Odstock Medical Limited's Industry?
How Carbon Intensive is Odstock Medical Limited's Location?
Odstock Medical Limited's Scope 3 Categories Breakdown
Most of their carbon footprint comes from suppliers and value chain emissions, with Scope 3 emissions accounting for 56% of total emissions under the GHG Protocol, with "Employee Commuting" being the largest emissions source at 35% of Scope 3 emissions.
Top Scope 3 Categories
Odstock Medical Limited's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Odstock Medical Limited has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
